Post-progression survival after atezolizumab plus carboplatin and etoposide as first-line chemotherapy in small cell lung cancer has a significant impact on overall survival

被引：5

作者：

Masubuchi, Ken ^{[1
]}

Imai, Hisao ^{[1
,2
]}

Wasamoto, Satoshi ^{[3
]}

Tsuda, Takeshi ^{[4
]}

Minemura, Hiroyuki ^{[5
]}

Nagai, Yoshiaki ^{[6
]}

Yamada, Yutaka ^{[7
]}

Kishikawa, Takayuki ^{[8
]}

Umeda, Yukihiro ^{[9
]}

Shiono, Ayako ^{[2
]}

Takechi, Hiroki ^{[3
]}

Shiihara, Jun ^{[6
]}

Kaira, Kyoichi ^{[2
]}

Kanazawa, Kenya ^{[5
]}

Taniguchi, Hirokazu ^{[4
]}

Kaburagi, Takayuki ^{[7
]}

Kagamu, Hiroshi ^{[2
]}

Minato, Koichi ^{[1
]}

机构：

[1] Gunma Prefectural Canc Ctr, Div Resp Med, Ota, Japan

[2] Saitama Med Univ, Comprehens Canc Ctr, Int Med Ctr, Dept Resp Med, Hidaka, Japan

[3] Saku Cent Hosp Adv Care Ctr, Div Resp Med, Saku, Nagano, Japan

[4] Toyama Prefectural Cent Hosp, Div Resp Med, Toyama, Japan

[5] Fukushima Med Univ, Dept Pulm Med, Fukushima, Japan

[6] Jichi Med Univ, Saitama Med Ctr, Dept Resp Med, Saitama, Japan

[7] Ibaraki Cent Hosp, Div Resp Med, Kasama, Ibaraki, Japan

[8] Tochigi Canc Ctr, Div Thorac Oncol, Utsunomiya, Tochigi, Japan

[9] Univ Fukui, Dept Internal Med 3, Fac Med Sci, Eiheiji, Japan

来源：

THORACIC CANCER | 2022年 / 13卷 / 19期

关键词：

atezolizumab; carboplatin; etoposide; overall survival; post-progression survival; SURROGATE END-POINTS; TUMOR RESPONSE; 2ND-LINE TREATMENT; PERFORMANCE; TOPOTECAN;

D O I：

10.1111/1759-7714.14621

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background The effect of first-line chemotherapy on overall survival (OS) may be significantly influenced by subsequent therapy for patients with extensive disease small cell lung cancer (ED-SCLC). Therefore, we evaluated the relationship between progression-free survival (PFS), post-progression survival (PPS), and OS of ED-SCLC patients treated with atezolizumab plus carboplatin and etoposide as first-line therapy. Methods We analyzed the data of 57 patients with relapsed ED-SCLC treated with atezolizumab plus carboplatin and etoposide (AteCE) as first-line chemotherapy between August 2019 and September 2020. The respective correlations between PFS-OS and PPS-OS following first-line AteCE treatment were examined at the individual patient level. Results Spearman's rank correlation analysis and linear regression analysis showed that PPS strongly correlated with OS (r = 0.93, p < 0.05, R-2 = 0.85) and that PFS moderately correlated with OS (r = 0.55, p < 0.05, R-2 = 0.28). Performance status at relapse (0-1/>= 2), number of cycles of atezolizumab maintenance therapy (<3/>= 3), and platinum rechallenge chemotherapy all significantly positively correlated with PPS (p < 0.05). Conclusions Upon comparing OS-PFS and OS-PPS in this patient population, OS and PPS were found to have a stronger correlation. These results suggest that performance status at relapse, atezolizumab maintenance, or chemotherapy rechallenge could affect PPS.

引用

页码：2776 / 2785

页数：10

共 35 条

[11] A statistical model for the dependence between progression-free survival and overall survival [J].

Fleischer, Frank ;

Gaschler-Markefski, Birgit ;

Bluhmki, Erich .

STATISTICS IN MEDICINE, 2009, 28 (21) :2669-2686

[12] Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer [J].

Foster, Nathan R. ;

Renfro, Lindsay A. ;

Schild, Steven E. ;

Redman, Mary W. ;

Wang, Xiaofei F. ;

Dahlberg, Suzanne E. ;

Ding, Keyue ;

Bradbury, Penelope A. ;

Ramalingam, Suresh S. ;

Gandara, David R. ;

Shibata, Taro ;

Saijo, Nagahiro ;

Vokes, Everett E. ;

Adjei, Alex A. ;

Mandrekar, Sumithra J. .

JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (07) :1099-1106

[13] Tumor Response and Progression-Free Survival as Potential Surrogate Endpoints for Overall Survival in Extensive Stage Small-Cell Lung Cancer Findings on the Basis of North Central Cancer Treatment Group Trials [J].

Foster, Nathan R. ;

Qi, Yingwei ;

Shi, Qian ;

Krook, James E. ;

Kugler, John W. ;

Jett, James R. ;

Molina, Julian R. ;

Schild, Steven E. ;

Adjei, Alex A. ;

Mandrekar, Sumithra J. .

CANCER, 2011, 117 (06) :1262-1271

[14] TENIPOSIDE IN THE TREATMENT OF SMALL-CELL LUNG-CANCER - THE INFLUENCE OF PRIOR CHEMOTHERAPY [J].

GIACCONE, G ;

DONADIO, M ;

BONARDI, G ;

TESTORE, F ;

CALCIATI, A .

JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (08) :1264-1270

[15] Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: Analysis of the surveillance, epidemiologic, and end results database [J].

Govindan, Ramaswamy ;

Page, Nathan ;

Morgensztern, Daniel ;

Read, William ;

Tierney, Ryan ;

Vlahiotis, Anna ;

Spitznagel, Edward L. ;

Piccirillo, Jay .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (28) :4539-4544

[16] Postprogression survival for first-line chemotherapy of patients with advanced non-small-cell lung cancer [J].

Hayashi, H. ;

Okamoto, I. ;

Morita, S. ;

Taguri, M. ;

Nakagawa, K. .

ANNALS OF ONCOLOGY, 2012, 23 (06) :1537-1541

[17] First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer [J].

Horn, L. ;

Mansfield, A. S. ;

Szczesna, A. ;

Havel, L. ;

Krzakowski, M. ;

Hochmair, M. J. ;

Huemer, F. ;

Losonczy, G. ;

Johnson, M. L. ;

Nishio, M. ;

Reck, M. ;

Mok, T. ;

Lam, S. ;

Shames, D. S. ;

Liu, J. ;

Ding, B. ;

Lopez-Chavez, A. ;

Kabbinavar, F. ;

Lin, W. ;

Sandler, A. ;

Liu, S. V. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (23) :2220-2229

[18] Role of Survival Post-Progression in Phase III Trials of Systemic Chemotherapy in Advanced Non-Small-Cell Lung Cancer: A Systematic Review [J].

Hotta, Katsuyuki ;

Kiura, Katsuyuki ;

Fujiwara, Yoshiro ;

Takigawa, Nagio ;

Hisamoto, Akiko ;

Ichihara, Eiki ;

Tabata, Masahiro ;

Tanimoto, Mitsune .

PLOS ONE, 2011, 6 (11)

[19] Individual-level data on the relationships of progression-free survival, post-progression survival and tumor response with overall survival in patients with advanced non-squamous non-small cell lung cancer [J].

Imai, H. ;

Takahashi, T. ;

Mori, K. ;

Ono, A. ;

Akamatsu, H. ;

Shukuya, T. ;

Taira, T. ;

Kenmotsu, H. ;

Naito, T. ;

Murakami, H. ;

Endo, M. ;

Nakajima, T. ;

Yamamoto, N. .

NEOPLASMA, 2014, 61 (02) :233-240

[20] Post-Progression Survival Influences Overall Survival among Patients with Advanced Non-Small Cell Lung Cancer Undergoing First-Line Pembrolizumab Monotherapy [J].

Imai, Hisao ;

Kishikawa, Takayuki ;

Minemura, Hiroyuki ;

Yamada, Yutaka ;

Ibe, Tatsuya ;

Mori, Keita ;

Yamaguchi, Ou ;

Mouri, Atsuto ;

Hamamoto, Yoichiro ;

Kanazawa, Kenya ;

Kasai, Takashi ;

Kaira, Kyoichi ;

Kaburagi, Takayuki ;

Minato, Koichi ;

Kobayashi, Kunihiko ;

Kagamu, Hiroshi .

ONCOLOGY, 2021, 99 (09) :562-570

← 1 2 3 4 →